Welcome to our dedicated page for Icad SEC filings (Ticker: ICAD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Trying to track how an FDA review, a new ProFound AI release, or Xoft therapy adoption shapes iCAD’s future? These events hide in dense SEC documents that easily top 250 pages and span multiple forms. Locating reimbursement risk language or pinpointing when executives sell shares just before a clinical milestone can feel impossible.
Stock Titan solves this. Our AI reads every iCAD quarterly earnings report 10-Q filing, iCAD annual report 10-K simplified, and iCAD 8-K material events explained the moment they hit EDGAR. Plain-language summaries highlight FDA clearances, segment revenue for Detection vs. Therapy, and critical R&D trends—answering the search you typed, from “iCAD SEC filings explained simply” to “how to read iCAD proxy statement executive compensation.” Real-time alerts surface iCAD insider trading Form 4 transactions so you can follow iCAD executive stock transactions Form 4 without digging through footnotes.
Whether you need to understand deferred revenue from subscription upgrades, compare ASPs across imaging modalities, or examine clinical trial spending, our platform brings every disclosure together:
- AI-powered summaries that turn regulatory jargon into key takeaways
- Live feed of iCAD Form 4 insider transactions real-time
- Side-by-side earnings trends with AI commentary for informed decisions
Stop scrolling thousands of lines in EDGAR. Start understanding iCAD SEC documents with AI—and make faster, evidence-based calls on this AI-driven cancer-detection leader.
THE GOLDMAN SACHS GROUP, INC. and Goldman Sachs & Co. LLC filed a Schedule 13G disclosing beneficial ownership of 1,452,580 shares of ICAD, Inc. common stock, representing 5.3% of the class. The filing shows shared voting and shared dispositive power over those shares and reports sole voting and dispositive power as 0. The statement affirms the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. A joint filing agreement and an exhibit identify Goldman Sachs & Co. LLC as a subsidiary and as a broker-dealer and registered investment adviser.
FAQ
What is the current stock price of Icad (ICAD)?
What is the market cap of Icad (ICAD)?
